Drugs /

cudc-907

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.

Clinical Trials

View Clinical Trials for cudc-907

Cudc-907 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating cudc-907, 2 are phase 1 (1 open).

ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for cudc-907 clinical trials.

Breast carcinoma, Burkitt lymphoma, and central nervous system neoplasm are the most common diseases being investigated in cudc-907 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cudc-907
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cudc-907
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cudc-907 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pi3k/hdac inhibitor cudc-907
NCIT ID [1]:
C104008

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.